PALI
PALISADE BIO, INC.
$1.74
0.00%
$293.3M
No data for this timeframe.
Vol
Market Cap$293.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders7 funds
Inst. Value$20.5M
Inst. Activity5 buys / 0 sells
Insider Activity0B / 2S
Insider Net $-$10.3K
SEC Reports4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001357459·Prev Close $1.74
Recent Activity
May 22, 2026
SEC
Palisade Bio's $300M universal shelf registration (File No. 333-295815) became effective on May 21, 2026, enabling the c
EFFECT — Impact 4/10
May 12, 2026
SEC
Palisade Bio filed a $300M universal shelf registration statement on Form S-3, concurrent with its Q1 2026 earnings rele
S-3 — Impact 5/10
Apr 29, 2026
SEC
PALISADE BIO, INC. filed DEFA14A additional definitive proxy soliciting materials. The substantive content is embedded i
DEFA14A — Impact 2/10
Feb 12, 2026
Insider
Finley John David sold 3,896 shares
CEO, CFO @ $1.75 ($6.8K)
Feb 12, 2026
Insider
Jones Mitchell Lawrence sold 1,989 shares
Chief Medical Officer @ $1.75 ($3.5K)
Feb 11, 2026
Insider
Finley John David sold 13,333 shares
CEO, CFO @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — DOUBLED
4,142,446 shares ($9.7M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — NEW
2,382,500 shares ($5.6M)
Price Targets
$9.71
+474.8% upside
Strong Buy
Current $1.69
Low $5.00
Median $7.00
High $25.00
7 analysts
$5.00
$25.00
Analyst Ratings
4Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 9, 2026 | Wolfe Research | INITIATE | Outperform |
| Mar 26, 2026 | HC Wainwright & Co. | INITIATE | Buy |
| Feb 25, 2026 | Stifel | INITIATE | Buy |
| Jan 9, 2026 | B. Riley Securities | INITIATE | Buy |
| Dec 30, 2025 | Clear Street | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 ▼ -9.4% | $-0.06 — $-0.04 | 91% YoY | 6 |
| Next Q | $-0.05 ▲ +13.9% | $-0.07 — $-0.04 | 86% YoY | 6 |
| Current FY | $-0.21 ▼ -9.4% | $-0.27 — $-0.18 | 30% YoY | 6 |
| Next FY | $-0.23 ▲ +16.1% | $-0.34 — $-0.18 | -12% YoY | 6 |
Latest Reports
NEUTRAL
EFFECT
4/10
Palisade Bio's $300M universal shelf registration (File No. 333-295815) became effective on May 21, 2026, enabling the c
May 22, 2026
NEUTRAL
S-3
5/10
Palisade Bio filed a $300M universal shelf registration statement on Form S-3, concurrent with its Q1 2026 earnings rele
May 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $9.7M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $5.6M | NEW |
| VANGUARD GROUP INC | $5.0M | NEW |
| BANK OF AMERICA CORP | $164.7K | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $65.0K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 12, 2026 | Finley John | SELL | $6.8K |
| Feb 12, 2026 | Jones Mitchell | SELL | $3.5K |
| Feb 11, 2026 | Finley John | M | $0.00 |
| Feb 11, 2026 | Finley John | M | $0.00 |
| Feb 11, 2026 | Jones Mitchell | M | $0.00 |
7 institutional holders with $20.5M total value (8,738,336 shares) as of 2025-Q4. Top holders: MORGAN, RENAISSANCE, VANGUARD. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 4,142,446 | $9.7M | 47.4% | DOUBLED +47967.4% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 2,382,500 | $5.6M | 27.3% | NEW |
| 3 | VANGUARD GROUP INC | 2,115,622 | $5.0M | 24.2% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 70,097 | $164.7K | 0.8% | DOUBLED +81408.1% |
| 5 | TWO SIGMA INVESTMENTS, LP | 27,640 | $65.0K | 0.3% | NEW |
| 6 | WELLS FARGO & COMPANY/MN | 21 | $49.00 | 0.0% | — |
| 7 | FMR LLC | 10 | $24.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 8,618 | 4,142,446 | +47967.4% | $9.7M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 2,382,500 | — | $5.6M | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 2,115,622 | — | $5.0M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 86 | 70,097 | +81408.1% | $164.7K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 27,640 | — | $65.0K | 2025-Q4 |
| UBS Group AG | DOUBLED | 332 | 19,413 | +5747.3% | $16.7K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 7 | 8,618 | +123014.3% | $7.4K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 45 | 86 | +91.1% | $73.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 38,083 | 332 | -99.1% | $226.00 | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 23 | 45 | +95.7% | $31.00 | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 628 | 7 | -98.9% | $5.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 8,974 | 38,083 | +324.4% | $25.9K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 7 | 628 | +8871.4% | $428.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 31 | 8,974 | +28848.4% | $14.8K | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 140 | 7 | -95.0% | $12.00 | 2024-Q4 |
2 unique insiders with 2 transactions. Net insider value: -$10.3K ($0.00 bought, $10.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | Finley John David | CEO, CFO | SELL | 3,896 | $1.75 | $6.8K |
| Feb 12, 2026 | Jones Mitchell Lawrence | Chief Medical Officer | SELL | 1,989 | $1.75 | $3.5K |
| Feb 11, 2026 | Finley John David | CEO, CFO | M | 13,333 | $0.00 | $0.00 |
| Feb 11, 2026 | Finley John David | CEO, CFO | M | 13,333 | $0.00 | $0.00 |
| Feb 11, 2026 | Jones Mitchell Lawrence | Chief Medical Officer | M | 8,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Jones Mitchell Lawrence | Chief Medical Officer | M | 8,000 | $0.00 | $0.00 |
| Feb 9, 2026 | Jones Mitchell Lawrence | Chief Medical Officer | A | 787,000 | $0.00 | $0.00 |
| Feb 9, 2026 | Finley John David | CEO, CFO | A | 2,011,000 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 4.0/10.
NEUTRAL
EFFECT
4/10
Palisade Bio's $300M universal shelf registration (File No. 333-295815) became effective on May 21,
May 22, 2026
NEUTRAL
S-3
5/10
Palisade Bio filed a $300M universal shelf registration statement on Form S-3, concurrent with its Q
May 12, 2026
NEUTRAL
DEFA14A
2/10
PALISADE BIO, INC. filed DEFA14A additional definitive proxy soliciting materials. The substantive c
Apr 29, 2026
NEUTRAL
8-K
5/10
Palisade Bio issued 1.54 million shares to an affiliate of Iterative Health for $3.0 million to supp
Apr 2, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 4 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$9.71 mean target
+474.8% upside
Strong Buy (3.00)
$5.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $1.69 |
| Target Low | $5.00 |
| Target Mean | $9.71 |
| Target Median | $7.00 |
| Target High | $25.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.06 | $-0.04 | 91.4% | -9.4% | 1↑ 3↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.05 | $-0.07 | $-0.04 | 86.4% | +13.9% | 2↑ 1↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-0.21 | $-0.27 | $-0.18 | 30.0% | -9.4% | 2↑ 2↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-0.23 | $-0.34 | $-0.18 | -11.9% | +16.1% | 3↑ 2↓ | $0.0B | 0.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.050 | |
| 7d ago | $-0.050 | |
| 30d ago | $-0.046 | -0.004 |
| 60d ago | $-0.052 | +0.002 |
| 90d ago | $-0.057 | +0.007 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 6 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 9, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Mar 26, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Feb 25, 2026 | Stifel | INITIATE | — | Buy |
| Jan 9, 2026 | B. Riley Securities | INITIATE | — | Buy |
| Dec 30, 2025 | Clear Street | INITIATE | — | Buy |
| Dec 29, 2025 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
What's up with Palisade Bio [NASDAQ: PALI]
▲ 1
💬 0
⚡ 0.5
Jun 9, 2026
other
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
<p align="center"><i>Presentation to highlight fibrostenotic Crohn’s disease biology and the potential of a locally bioactivated PDE4 inhibitor prodru
Jun 9, 2026
short_volume
Short Volume: PALI — 67.0% short (0.6M / 0.8M)
Short: 555,167 | Exempt: 0 | TRF Vol: 829,002 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: PALI — 67.1% short (1.4M / 2.1M)
Short: 1,433,195 | Exempt: 100 | TRF Vol: 2,136,828 | Short Ratio: 67.1% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: PALI — 65.1% short (0.9M / 1.4M)
Short: 892,366 | Exempt: 138 | TRF Vol: 1,370,343 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: PALI — 65.6% short (0.6M / 0.9M)
Short: 564,968 | Exempt: 0 | TRF Vol: 861,195 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
<p align="center"><i>Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD</i></p>
May 11, 2026
earnings_calendar
PALI Q1 2026 Earnings Scheduled — 2026-05-11
May 5, 2026
other
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
<p align="center"><i>Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing
Apr 16, 2026
other
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
<p align="center"><i>Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT</i></p>
Mar 30, 2026
other
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
<p align="justify"><strong>Carlsbad, CA, March 30, 2026 (GLOBE NEWSWIRE) -- </strong>Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”)
Mar 23, 2026
earnings_calendar
PALI Q4 2025 Earnings After Market Close — 2026-03-23